Double-Blind, Placebo-Controlled Study of Pyridostigmine in Postural Tachycardia Syndrome

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 15
Maximum Age: 55
Healthy Volunteers: No
View:

• Diagnosis of postural tachycardia syndrome using the following criteria:

• Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt.

• Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking.

• Both criteria must be fulfilled.

Locations
United States
Minnesota
Mayo Clinic
Recruiting
Rochester
Time Frame
Start Date: October 2006
Estimated Completion Date: February 2023
Participants
Target number of participants: 50
Treatments
Active Comparator: pyridostigmine
Active study drug
Placebo Comparator: Placebo
Control
Sponsors
Collaborators: National Institutes of Health (NIH)
Leads: Mayo Clinic

This content was sourced from clinicaltrials.gov

Similar Clinical Trials